Direct-to-Practice: Cross-Setting Strategies for Improved Management of Homozygous Hypercholesterolemia in Cardiology Settings

Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C), leading to premature cardiovascular disease. Affected individuals are typically less responsive or unresponsive to standard lipid-lowering therapies (ie, statins and PCSK9 inhibitors) and may benefit from treatments with alternative mechanisms of action, such as the recently FDA-approved ANGPTL3 inhibitor evinacumab. With this in mind, this program has been designed to educate clinicians about the prevalence of HoFH, the importance of HoFH screening, and the benefits and limitations of current therapies for lipid management in patients with the disease.

Upon completion of this educational activity, participants should be able to:

• Contrast the estimated prevalence versus the number of patients diagnosed with familial hypercholesterolemia (FH)
• Employ cascade screening to ensure case identification in first degree relatives of patients with HoFH
• Utilize currently available therapies for appropriate treatment of patients with HoFH

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM. 

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Mary P. McGowan, MD 
Consultant: Novartis
Speaker: Abbott

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.